Paula A Lewis

US Patent:

7691593, Apr 6, 2010

Filed:

Dec 3, 2003

Appl. No.:

10/727195

Inventors:

Carmen Pepicelli - Lowell MA, US
Paula Lewis - Cambridge MA, US
Andrew P. McMahon - Lexington MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

G01N 33/574
C12N 5/08

US Classification:

435 723, 435371, 435375, 800 10

Abstract:

The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e. g. , by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog therapeutic, a ptc therapeutic, or an FGF-10 therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e. g. , relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.

US Patent:

20090054398, Feb 26, 2009

Filed:

Mar 9, 2007

Appl. No.:

12/282211

Inventors:

Kevin Hudson - Cheshire, GB
Naomi Laing - Waltham MA, US
Paula Lewis - Waltham MA, US

Assignee:

ASTRAZENECA AB - Sodertalje

International Classification:

A61K 31/553
A61K 31/554
A61K 31/551
A61K 31/55
A61P 35/04

US Classification:

51421103, 51421203, 514218, 51421208

Abstract:

The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt form or in the form of a pharmaceutically acceptable solvate of the compound or the salt, to a human or animal patient in need thereof.

US Patent:

20110124580, May 26, 2011

Filed:

Mar 22, 2010

Appl. No.:

12/728948

Inventors:

Carmen V. Pepicelli - Lowell MA, US
Paula M. Lewis - Cambridge MA, US
Andrew P. McMahon - Lexington MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 38/16
C12N 5/071
A61K 31/7088
A61P 43/00

US Classification:

514 212, 435325, 514 213, 514 44 R

Abstract:

The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog therapeutic, a ptc therapeutic, or an FGF-10 therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e.g., relative to the absence of administration of the hedgehog therapeutic or ptc therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.

US Patent:

20130085096, Apr 4, 2013

Filed:

Aug 30, 2012

Appl. No.:

13/599879

Inventors:

Carmen Pepicelli - North Andover MA, US
Paula Lewis - Cambridge MA, US
Andrew P. McMahon - Lexington MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 38/17
C12N 5/071

US Classification:

514 15, 514 11, 514 17, 514 192, 435375

Abstract:

The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog therapeutic, a ptc therapeutic, or an FGF-10 therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e.g., relative to the absence of administeration of the hedgehog therapeutic or ptc therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.

US Patent:

20180369413, Dec 27, 2018

Filed:

Jun 19, 2018

Appl. No.:

16/012138

Inventors:

- Lexington MA, US
Frank DeRosa - Lexington MA, US
Jonathan Cherry - Lexington MA, US
Paula Lewis - Lexington MA, US
Shrirang Karve - Lexington MA, US
Zarna Patel - Lexington MA, US
Darshan Parekh - Lexington MA, US
Susan Wood - Lexington MA, US
Chi-Sung Chiu - Lexington MA, US
Caroline J. Woo - Lexington MA, US

International Classification:

A61K 48/00
C12N 15/62
A61K 38/02
C12N 15/52
A61K 38/17
A61P 21/00
A61K 9/127

Abstract:

The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.